Investment Rating - The investment rating for the company is "Accumulate" (首次覆盖) [3][6]. Core Views - The company achieved a revenue of 3.524 billion yuan in 2024, representing a year-on-year growth of 3.4%. However, the net profit attributable to shareholders decreased by 22.08% to 249 million yuan [3][5]. - The company benefits from the domestic high-end and new high-temperature alloy production scale, with significant growth in overseas markets, particularly in sectors related to the Belt and Road Initiative, where revenue growth reached 54.08% [5][6]. - The industry outlook is positive, with a strong upward trend in demand for military and civil aviation engines, supported by a 7.2% increase in national defense spending in 2025 [5][6]. Financial Performance Summary - Revenue for 2024 was 3.524 billion yuan, with a growth rate of 3.4%. The forecast for 2025 is 3.824 billion yuan, reflecting an expected growth rate of 8.51% [7]. - The net profit for 2024 was 249 million yuan, with projections of 288 million yuan for 2025, indicating a recovery with a growth rate of 15.93% [7]. - The company's gross margin is expected to improve, with a forecasted gross margin of 30.40% in 2025 [10]. Market and Product Insights - The company focuses over 60% of its products on the aerospace sector, which is expected to see robust growth in both military and civil aviation engine demands [5][6]. - The company is actively expanding its domestic and international markets, with significant potential in low-altitude economy and gas turbine sectors [5][6]. - The product structure is anticipated to optimize further, enhancing overall profitability and net profit margins in the coming years [5][6].

公 司 报 告 医药 2025年04月28日 鱼跃医疗(002223.SZ) 家用器械保持国内市场领先地位，海外提供新的增长动能 强烈推荐( 维持) 整体业绩在高基数下承压，业务逐步回归常态化发展轨道。分业务板块 来看： 股价:33.21元 主要数据 | 行业 | 医药 | | --- | --- | | 公司网址 | www.yuwell.com | | 大股东/持股 | 江苏鱼跃科技发展有限公司/24.54% | | 实际控制人 | 吴光明 | | 总股本(百万股) | 1,002 | | 流通A股(百万股) | 940 | | 流通B/H股(百万股) | | | 总市值(亿元) | 333 | | 流通A股市值(亿元) | 312 | | 每股净资产(元) | 13.07 | | 资产负债率(%) | 19.4 | 行情走势图 证券分析师 事项： 2024年公司实现营业收入75.66亿元，同比-5.09%，实现归母净利润18.06亿 元，同比-24.63%。2024年公司拟向全体股东每10股派发现金红利4.00元（含 税）。2025年Q1公司营业收入24.36亿元，同比+9.17%，实现归母净利润 6. ...

以下文章来源于硬氪 ，作者张子怡 硬氪 . 专注全球化、硬科技报道。36kr旗下官方账号。 非洲兄弟的生意还好做吗？ 文 ｜ 张子怡 编辑 ｜ 袁斯来 来源｜ 硬氪（ID： south_36kr） 封面来源 ｜ 企业官网 手机市场的战火，如今在没什么利润的地方也烧得铺天盖地。 在传音控股每一年的年报里，都能看到他们为了海外用户耗费心力。 尤其是，传音引以为傲的大本营非洲市场中，小米和Realme的增速都异常迅猛，Realme同比增速超89%。传音在非洲独特的分销渠道网络建设，曾经让 国内手机厂商望而却步，但在今天，各家逐渐学会了传音的路数。 对于业绩的增收不增利，传音回应称，受市场竞争以及供应链成本综合影响，毛利率有所下降，扣非净利润因此有所减少。 简单解释原因，就是新兴市场竞争显著加剧。传音在受到巨头持续的冲击。 小米除性价比之外，还着力结合本地化拉动"米粉"；Vivo则主攻本土化出海战略；Realme则主打年轻潮流人群。 东南亚、拉美、中东市场同样如此。各家的目标很明确：瓜分传音的份额。 低价路线是传音的优势，也使得其难以向上做高端化。智能手机供应链高度成熟的今天，大厂一旦下定决心要流血占地，传音很难抵御 ...

证券代码：300470 股票简称：中密控股 中密控股股份有限公司投资者关系活动记录表 编号：2025-003 投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人 员姓名 线上参与中密控股 2024 年度网上业绩说明会的投资者 时间 2025 年 04 月 28 日（星期一）下午 15:00-17:00 地点 "中密控股投资者关系"微信小程序 上市公司接待人员 姓名 董事长：彭玮先生 董事、总经理：陈虹先生 独立董事：应千伟先生 董事会秘书：沈小华先生 财务总监：刘小强先生 投资者关系活动主 要内容介绍 1、问：2024 年公司营业收入和净利润都实现了稳健增 长，能否详细介绍一下推动业绩增长的主要因素是什 么？ 答：投资者您好。2024 年度，公司的下游行业面对的需 求持续较低迷，管理层与全体员工齐心协力、真抓实干， 使得公司经营业绩仍然保持了稳健增长。其中：（1） 机械密封板块，增量市场收入略高于存量市场，增量市 场收入及存量市场收入与去年同比均有一定增幅，增量 市场毛利率同比基本维持稳定，存 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 亚辉龙(688575) 投资评级 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 发光表现亮眼，降本增效助力利润加 速增长 装机持续推进，自产发光实现 50%高增 长 点评： 请阅读最后一页免责声明及信息披露 http://www.cindasc.com 1 ➢ 发光业务表现亮眼，国际化进展顺利，海外收入快速增长。2024 年公 司实现营业收入 20.12 亿元（yoy-2.02%），主要是因为新冠业务较去 年同期大幅下降，近年来公司加大自产产品市场推广，非新冠自产业务 保持快速发展，实现收入 16.72 亿元（yoy+26.13%）。非新冠自产业 务分结构来看，发光业务得益于仪器装机量提升、特色项目带动常规试 剂放量增 ...

投资者关系活动记录表 编号：20250428 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 √业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称 及人员姓名 | 通过全景网参与冀凯股份 2024 年度网上业绩说明会的投资者 | | 时间 2025 | 年 4 月 28 日 15:00-16:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待 | 董事长：冯帆先生 独立董事：徐超智女士 | | 人员姓名 | 财务负责人：乔贵彩女士 | | | 董事会秘书：田季英女士 | | 投资者关系活动 | 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、公司 2024 年研发投入占营业收入的比例为 | | | 5.47%，请问未来 | | | 是否有计划进一步增加研发投入，以推动技术创新和产品升级？ | | 主要内容介绍 | 您好，感谢对公司的关注。公司 ...

2025 年 4 月 28 日 公司研究 业绩稳健增长，新品推出与海外拓展支撑未来成长 ——伊之密（300415.SZ）2024 年年报报、2025 年一季报点评 要点 24 年及 25Q1 业绩均实现同比稳健增长 伊之密 24 年实现营业收入 50.6 亿元，同比增长 23.6%；归母净利润 6.1 亿元，同比增长 27.4%。公司 24 年毛利率为 31.9%，同比下降 1.3 个百分点； 净利率为 12.4%，同比上升 0.4 个百分点。24 年经营性现金净流入 3.6 亿元， 同比增长 104.9%。公司拟分红每股 0.50 元（含税），分红率为 38.9%。 公司 25Q1 业绩保持快速增长，实现营业收入 11.9 亿元，同比增长 24.3%； 归母净利润 1.3 亿元，同比增长 14.3%；毛利率为 30.6%，同比下降 4.2 个百分 点；净利率为 11.5%，同比下降 0.9 个百分点。 2025 年 4 月 23 日，公司发布公告，拟以 1500-2500 万元资金回购股份， 回购价格不超过 28 元/股，占当前总股本比例为 0.11%-0.19%。此次回购彰显 了公司对未来长期发展的信心。 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 鱼跃医疗(002223) | 投资评级 | 买入 | | --- | --- | | 上次评级 | 买入 | [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] "产品+营销"双轮驱动，塑造家用医疗 器械领先品牌 业务发展稳定势好，创新发展布局多 元领域 鱼跃医疗（002223）核心板块稳定增 长，电商渠道表现优异 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 血糖业务增长 40%，海外拓展成效凸显 [Table_ReportDate] 2025 年 04 月 28 日 [Table_S 事件：公司发布 umma ...

Investment Rating - The investment rating for the company is "Buy" and it is maintained [1] Core Views - The company is experiencing short-term performance pressure but is expected to improve gradually on a quarterly basis. The revenue for 2024 is projected at 2.257 billion yuan, with a year-on-year growth of 22.18% [4][9] - The company is focusing on stabilizing its existing products while expanding its new product offerings. The revenue from various product segments shows significant growth, particularly in comprehensive nuts and beans [5] - The company is actively enhancing its sales channels, with notable performance in overseas markets, especially in Southeast Asia [5][8] Company Overview - Latest closing price: 74.53 yuan - Total shares: 0.93 billion, circulating shares: 0.50 billion - Total market value: 6.9 billion yuan, circulating market value: 3.7 billion yuan - 52-week high/low: 93.52/47.85 yuan - Debt-to-asset ratio: 24.5% - Price-to-earnings ratio: 18.00 [3] Financial Performance - For 2024, the company reported operating income of 2.257 billion yuan, net profit attributable to shareholders of 376 million yuan, and a non-recurring net profit of 341 million yuan, with respective year-on-year growth rates of 22.18%, 14.32%, and 16.91% [4] - The company’s gross margin and net margin for 2024 were 35.46% and 16.67%, showing slight declines compared to the previous year [6] - The profit forecast for 2025 and 2026 has been adjusted to 2.677 billion yuan and 3.102 billion yuan in revenue, with net profits of 402 million yuan and 496 million yuan respectively [9][11] Strategic Focus - The company plans to expand into new markets in Southeast Asia, with a focus on localizing product designs and increasing brand presence [7] - The strategy includes strengthening partnerships with major retail channels and enhancing e-commerce collaborations to drive growth [8] - Cost control measures are being implemented, particularly in raw material procurement, to improve profitability [8]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's blood glucose business has shown a remarkable growth of 40%, with significant results from overseas expansion, leading to an overall revenue increase of over 30% [2] - In 2024, the company reported a revenue of 7.566 billion yuan, a year-on-year decrease of 5.09%, and a net profit attributable to shareholders of 1.806 billion yuan, down 24.63% year-on-year [2] - The company is expected to maintain stable growth in its core segments, with a focus on enhancing its product matrix and brand influence, particularly in overseas markets [2] Financial Performance Summary - In 2024, the company achieved total revenue of 75.66 billion yuan, with domestic revenue at 65.74 billion yuan (down 8.58% year-on-year) and overseas revenue at 9.49 billion yuan (up 30.42% year-on-year) [2] - The blood glucose management and POCT solutions business generated revenue of 10.30 billion yuan, reflecting a growth of 40.20% [2] - The company’s gross profit margin for 2024 was 50.14%, a decrease of 1.35 percentage points year-on-year, while the net profit margin was 23.85%, down 5.96 percentage points year-on-year [2] Revenue and Profit Forecast - The company is projected to achieve revenues of 86.82 billion yuan, 100.07 billion yuan, and 115.20 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 14.7%, 15.3%, and 15.1% [2] - The net profit attributable to shareholders is expected to be 2.111 billion yuan, 2.494 billion yuan, and 2.930 billion yuan for the same years, with growth rates of 16.9%, 18.2%, and 17.5% [2] - The price-to-earnings ratio (P/E) for 2025 is projected to be 16 times [2]